|
|
|
|
Hyperglycemia Not Due to Diabetes Mellitus
Finlayson C et al.Intercurrent illness may trigger hyperglycemia as a result of the secretion of stress hormones and cytokines. This condition is termed "stress hyperglycemia." Patients with stress hyperglycemia usually do not have a lengthy history of...
|
|
|
Type 2 Diabetes
Other Names of : - Non-Insulin-Dependent Diabetes Mellitus (NIDDM), Adult-Onset Diabetes Diabetes mellites (DM) is a metabolic disease which makes it challenging for the affected individuals to convert food to energy.This leads to...
|
|
|
Repros Therapeutics receives FDA confirmation for initiating Androxal IND
Repros Therapeutics Inc.(NasdaqCM:RPRX) today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may initiate its Investigational New Drug...
|
|
|
Repros' New IND for the Investigation of Androxal in the Treatment of Type II Diabetes in Men with Secondary H
- Repros Therapeutics Inc.(NasdaqCM:RPRX) today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may initiate its Investigational New Drug...
|
|
|
Repros New IND for the Investigation of Androxal in the Treatment of Type II Diabetes in Men with Secondary Hypogonadism is Now Effective
Repros New IND for the Investigation of Androxal in the Treatment of Type II Diabetes in Men with Secondary Hypogonadism is Now Effective News source: Business Wire Repros Therapeutics Inc.(NasdaqCM:RPRX) today announced that the Company has received...
|
|
|
Repros New IND for the Investigation of Androxal in the Treatment of Type II Diabetes in Men with Secondary Hypogonadism ..
Repros New IND for the Investigation of Androxal in the Treatment of Type II Diabetes in Men with Secondary Hypogonadism is Now Effective Refer to a friend Business Wire 2010 Repros Therapeutics Inc.(NasdaqCM:RPRX) today announced that the Company has...
|
|
|
Repros New IND for the Investigation of Androxal in the Treatment of Type II Diabetes in Men with Secondary Hypogonadism is Now Effective
THE WOODLANDS, Texas-- (BUSINESS WIRE) -- (NasdaqCM:RPRX) today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may initiate its Investigational...
|
|
|
Repros New IND for the Investigation of Androxal in the Treatment of Type II Diabetes in Men with Seconda
Repros Therapeutics Inc.(NasdaqCM:RPRX) today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may initiate its Investigational New Drug...
|
|
|
Repros' New IND for the Investigation of Androxal(R) in the Treatment of Type II Diabetes in Men with Secondary Hypogonadism is Now Effective
(BUSINESS WIRE) ----Repros Therapeutics Inc.(NasdaqCM:RPRX) today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may initiate its...
|
|
|
Repros' New IND for the Investigation of Androxal(R) in the Treatment of Type II Diabetes in
BusinessWire - Repros Therapeutics Inc.(NasdaqCM:RPRX) today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may initiate its Investigational...
|
|
|
Repros New IND for the Investigation of Androxal(R) in the Treatment of Type II Diabetes in Men with Secondary Hypogonadism is Now Effective
THE WOODLANDS, Texas--(BUSINESS WIRE)-- Repros Therapeutics Inc.(NasdaqCM: RPRX) today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may...
|
|
|
Repros' New IND for the Investigation of Androxal(R) in the Treatment of Type II Diabetes in Men with Secondary Hypogonadism is Now Effective
THE WOODLANDS, Texas--(BUSINESS WIRE)-- Repros Therapeutics Inc.(NasdaqCM: RPRX) today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may...
|
|
|
Repros' New IND for the Investigation of Androxal(R) in the Treatment of Type II Diabetes in Men with Secondary Hypogonadism is Now Effective
THE WOODLANDS, Texas--(BUSINESS WIRE)-- Repros Therapeutics Inc.(NasdaqCM: RPRX) today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may...
|
|
|
ReprosEUR New IND for the Investigation of Androxal in the Treatment of Type II Diabetes
Repros Therapeutics Inc.(NasdaqCM:RPRX) today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may initiate its Investigational New Drug...
|
|
|
Repros' New IND for the Investigation of Androxal(R) in the Treatment of Type II Diabetes in Men with Secondar
Repros Therapeutics Inc.(NasdaqCM:RPRX) today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may initiate its Investigational New Drug...
|
|
|
Repros' New IND for the Investigation of Androxal in the Treatment of Type II Diabetes in Men with Secondary
THE WOODLANDS, Texas (Business Wire) -- Repros Therapeutics Inc.(NasdaqCM:RPRX) today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may...
|
|
|
Repros' New IND for the Investigation of Androxal in the Treatment of Type II Diabetes in Men with Secondary Hypogonadis
m is Now Effective THE WOODLANDS, Texas - (BUSINESS WIRE) - Repros Therapeutics Inc.(NasdaqCM:RPRX) today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that...
|
|
|
Postoperative Infection Rates in Foot and Ankle Surgery: A Comparison of Patients with and without Diabetes Mellitus
Wukich DK et al.Patients with diabetes mellitus are at increased risk of severe infection compared with those without diabetes. Postoperative Infection Rates in Foot and Ankle Surgery: A Comparison of Patients with and without Diabetes Mellitus....
|
|
|
Skipping Meals or Carbohydrate-Free Meals in Order to Determine Basal Insulin Requirements in Subjects with Type 1 Diabetes Mellitus
Uthoff H et al.Plasma glucose concentrations significantly increase in patients with type 1 diabetes following the intake of carbohydratefree meals. Skipping Meals or Carbohydrate-Free Meals in Order to Determine Basal Insulin Requirements in Subjects with...
|
|
|
ACE Inhibitor and Angiotensin II Type 1 Receptor Antagonist Therapies in Elderly Patients with Diabetes Mellitus: Are They Underutilized?
Pappoe LS et al.ACE Inhibitor and Angiotensin II Type 1 Receptor Antagonist Therapies in Elderly Patients with Diabetes Mellitus: Are They Underutilized?.
|
|
|
Gestational Diabetes Mellitus
_ Gestational Diabetes Mellitus.
|
|
|
Effects of Intravenous Glucose Load on Insulin Secretion in Patients with Ketosis-Prone Diabetes Mellitus during Near-Normoglycemia Remission
Critical Care Medicine, 01/22/10 Relevance Score: 65%% Metabolism-Clinical and Experimental, 01/04/10 Relevance Score: 65%% Metabolism-Clinical and Experimental, 12/26/09 Relevance Score: 65%% Diabetes Care, 12/16/09 Relevance Score: 65%% S Effects of...
|
|
|
Changes in Prandial Glucagon Levels after 2-year Treatment with Vildagliptin or Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy
Ahren B et al.The objective was to determine if the dipeptidyl peptidase 4 inhibitor vildagliptin more effectively than the sulfonylurea glimepiride inhibits glucagon levels during meal. Changes in Prandial Glucagon Levels after 2-year Treatment with...
|
|
|
Paclitaxel-Eluting Versus Sirolimus-Eluting Stents in Diabetes Mellitus
Wolf WM et al.Paclitaxel-Eluting Versus Sirolimus-Eluting Stents in Diabetes Mellitus.
|
|
|
FDA Approves Liraglutide in Patients with Type 2 Diabetes Mellitus Failing First-Line Treatment
_ FDA Approves Liraglutide in Patients with Type 2 Diabetes Mellitus Failing First-Line Treatment.
|
